Chongqing Zhifei Biological Products (300122.SZ) Receives Acceptance for Clinical Trial Application of Freeze-Dried Varicella Inactivated Vaccine

Stock News2025-11-12

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. ("Zhifei Longcom"), has received the acceptance notice from the National Medical Products Administration (NMPA) for the clinical trial application of its freeze-dried varicella inactivated vaccine (Acceptance No.: CXSL2500962).

If no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with the clinical trials as per the submitted protocol.

The freeze-dried varicella inactivated vaccine, developed by Zhifei Longcom, adopts an innovative inactivated technology route, with both the production cell line and virus strain independently developed by the company. The product demonstrates significant safety advantages and is intended for the prevention of varicella in individuals aged 12 months and above. It offers a safer vaccination option for healthy individuals as well as those with immunodeficiency or contraindications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153620081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153620081","market":"hk","top_or_hot":-1,"title":"Chongqing Zhifei Biological Products (300122.SZ) Receives Acceptance for Clinical Trial Application of Freeze-Dried Varicella Inactivated Vaccine","media":"Stock News","content":"<p>Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance notice from the National Medical Products Administration (NMPA) for the clinical trial application of its freeze-dried varicella inactivated vaccine (Acceptance No.: CXSL2500962).</p>\n<p>If no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with the clinical trials as per the submitted protocol.</p>\n<p>The freeze-dried varicella inactivated vaccine, developed by Zhifei Longcom, adopts an innovative inactivated technology route, with both the production cell line and virus strain independently developed by the company. The product demonstrates significant safety advantages and is intended for the prevention of varicella in individuals aged 12 months and above. It offers a safer vaccination option for healthy individuals as well as those with immunodeficiency or contraindications.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Zhifei Biological Products (300122.SZ) Receives Acceptance for Clinical Trial Application of Freeze-Dried Varicella Inactivated Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Zhifei Biological Products (300122.SZ) Receives Acceptance for Clinical Trial Application of Freeze-Dried Varicella Inactivated Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-12 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance notice from the National Medical Products Administration (NMPA) for the clinical trial application of its freeze-dried varicella inactivated vaccine (Acceptance No.: CXSL2500962).</p>\n<p>If no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with the clinical trials as per the submitted protocol.</p>\n<p>The freeze-dried varicella inactivated vaccine, developed by Zhifei Longcom, adopts an innovative inactivated technology route, with both the production cell line and virus strain independently developed by the company. The product demonstrates significant safety advantages and is intended for the prevention of varicella in individuals aged 12 months and above. It offers a safer vaccination option for healthy individuals as well as those with immunodeficiency or contraindications.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1153620081","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153620081","pubTimestamp":1762939839,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300122":"智飞生物","BK0196":"行业龙头","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0077":"质押式回购","BK0188":"融资融券","BK0046":"生物疫苗","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0239":"医药制造","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC"},"translate_title":"重庆智飞生物制品（300122.SZ）冻干水痘灭活疫苗临床试验申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300122":1},"content_text":"Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (\"Zhifei Longcom\"), has received the acceptance notice from the National Medical Products Administration (NMPA) for the clinical trial application of its freeze-dried varicella inactivated vaccine (Acceptance No.: CXSL2500962).\nIf no negative or questioning opinions are received from the Center for Drug Evaluation (CDE) within 60 days from the acceptance date, Zhifei Longcom may proceed with the clinical trials as per the submitted protocol.\nThe freeze-dried varicella inactivated vaccine, developed by Zhifei Longcom, adopts an innovative inactivated technology route, with both the production cell line and virus strain independently developed by the company. The product demonstrates significant safety advantages and is intended for the prevention of varicella in individuals aged 12 months and above. It offers a safer vaccination option for healthy individuals as well as those with immunodeficiency or contraindications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153620081","isCrawlerRequest":true}